supported by the Natural Science Foundation of China(Nos.82273804,81973195,81872891,and 81973203);the Southerm Marine Science and Engineering Guangdong Laboratory(Zhuhai)(No.SML2021SP301,China);Open Program of Shenzhen Bay Laboratory(No.SZBL2021080601007,China);the Guangdong Natural Science Funds for Distinguished Young Scholar(No.2019B151502016,China);Guangdong-Hong Kong-Macao research team project of the Guangdong Basic and Applied Basic Research Foundation(No.2022B1515130008,China).
Nuclear transporter importin-β1 is emerging as an attractive target by virtue of its prevalence in many cancers.However,the lack of druggable inhibitors restricts its therapeutic proof of concept.In the present work,...
Purpose: The purpose of this paper is to discuss the most important facts about prostate cancer, its treatments and efficacy, the type of prostate cancer that does not improve with hormonal therapy (Castration-Resista...
supported by the National Natural Science Foundation of China(Grant Nos.81672550 and 81974395);Guangdong Basic and Applied Basic Research Foundation(Grant No.2019A1515011437);Guangzhou Science and Technology Cooperation Program(Foreign Research and Development Cooperation)(Grant No.201807010087);Clinical Research 5010 Program of Sun Yat-sen University(Grant No.2019005);Sun Yat-Sen Clinical Research and Cultivation Project of Sun Yat Sen University(Grant No.201702)to Hai Huang;supported by the National Natural Science Foundation of China(Grant No.81702527);supported by the China Scholarship Council(Grant No.201906380075).
Objective:To explore the genetic changes in the progression of castration-resistant prostate cancer(CRPC)and neuroendocrine prostate cancer(NEPC)and the reason why these cancers resist existing therapies.Methods:We em...